▶ 調査レポート

肺がん治療用免疫チェックポイント阻害剤のグローバル市場(~2027):CTLA-4阻害剤、PD-1阻害剤、PD-L1阻害剤

• 英文タイトル:Immune Checkpoint Inhibitors for Lung Cancer Market Research Report by Types, Products, End-Users, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Immune Checkpoint Inhibitors for Lung Cancer Market Research Report by Types, Products, End-Users, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「肺がん治療用免疫チェックポイント阻害剤のグローバル市場(~2027):CTLA-4阻害剤、PD-1阻害剤、PD-L1阻害剤」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2304J0224
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、259ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥732,452 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,472,452 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社の本調査資料によると、世界の肺がん治療用免疫チェックポイント阻害剤市場規模は、2021年784.91百万ドルから2022年に892.00百万ドルへと拡大、その後2027年までに年平均14.07%成長して1,730.01百万ドルに達する見通しです。本書は、肺がん治療用免疫チェックポイント阻害剤の世界市場を対象とした調査・分析結果を整理したものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別分析(CTLA-4阻害剤、PD-1阻害剤、PD-L1阻害剤)、製品別分析(アテゾリズマブ、デュルバルマブ、ニボルマブ、ペムブロリズマブ)、エンドユーザー別分析(学術&研究機関、病院、製薬&バイオテクノロジー企業)、地域別分析(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)、競争状況、企業情報などの項目を掲載しています。なお、本書には、AbbVie Inc.、AstraZeneca plc、Bayer AG、BeyondSpring Pharmaceuticals Inc.、BioLineRx Ltd.、BridgeBio Inc.、Bristol-Myers Squibb Company、Celgene Corporation、F. Hoffmann-La Roche AG、Genentech, Inc.、IQVIA Inc.、Jazz Pharmaceuticalsなどの企業情報が含まれています。

・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の肺がん治療用免疫チェックポイント阻害剤市場規模:種類別
- CTLA-4阻害剤の市場規模
- PD-1阻害剤の市場規模
- PD-L1阻害剤の市場規模
・世界の肺がん治療用免疫チェックポイント阻害剤市場規模:製品別
- アテゾリズマブの市場規模
- デュルバルマブの市場規模
- ニボルマブの市場規模
- ペムブロリズマブの市場規模
・世界の肺がん治療用免疫チェックポイント阻害剤市場規模:エンドユーザー別
- 学術&研究機関における市場規模
- 病院における市場規模
- 製薬&バイオテクノロジー企業における市場規模
・世界の肺がん治療用免疫チェックポイント阻害剤市場規模:地域別
- 南北アメリカの肺がん治療用免疫チェックポイント阻害剤市場規模
アメリカの肺がん治療用免疫チェックポイント阻害剤市場規模
カナダの肺がん治療用免疫チェックポイント阻害剤市場規模
ブラジルの肺がん治療用免疫チェックポイント阻害剤市場規模
...
- アジア太平洋の肺がん治療用免疫チェックポイント阻害剤市場規模
日本の肺がん治療用免疫チェックポイント阻害剤市場規模
中国の肺がん治療用免疫チェックポイント阻害剤市場規模
インドの肺がん治療用免疫チェックポイント阻害剤市場規模
韓国の肺がん治療用免疫チェックポイント阻害剤市場規模
台湾の肺がん治療用免疫チェックポイント阻害剤市場規模
...
- ヨーロッパ/中東/アフリカの肺がん治療用免疫チェックポイント阻害剤市場規模
イギリスの肺がん治療用免疫チェックポイント阻害剤市場規模
ドイツの肺がん治療用免疫チェックポイント阻害剤市場規模
フランスの肺がん治療用免疫チェックポイント阻害剤市場規模
ロシアの肺がん治療用免疫チェックポイント阻害剤市場規模
...
- その他地域の肺がん治療用免疫チェックポイント阻害剤市場規模
・競争状況
・企業情報

The Global Immune Checkpoint Inhibitors for Lung Cancer Market size was estimated at USD 784.91 million in 2021 and expected to reach USD 892.00 million in 2022, and is projected to grow at a CAGR 14.07% to reach USD 1,730.01 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Immune Checkpoint Inhibitors for Lung Cancer to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Types, the market was studied across CTLA-4 Inhibitors, PD-1 Inhibitors, and PD-L1 Inhibitors.

Based on Products, the market was studied across Atezolizumab, Durvalumab, Nivolumab, and Pembrolizumab.

Based on End-Users, the market was studied across Academic & Research Institutes, Hospitals, and Pharmaceutical & Biotechnology Companies.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Immune Checkpoint Inhibitors for Lung Cancer market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Immune Checkpoint Inhibitors for Lung Cancer Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Immune Checkpoint Inhibitors for Lung Cancer Market, including AbbVie Inc., AstraZeneca plc, Bayer AG, BeyondSpring Pharmaceuticals Inc., BioLineRx Ltd., BridgeBio Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche AG, Genentech, Inc., IQVIA Inc., Jazz Pharmaceuticals, Mirati Therapeutics Inc., Ono Pharmaceutical Co. Ltd, and Philogen S.p.A..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Immune Checkpoint Inhibitors for Lung Cancer Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Immune Checkpoint Inhibitors for Lung Cancer Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Immune Checkpoint Inhibitors for Lung Cancer Market?
4. What is the competitive strategic window for opportunities in the Global Immune Checkpoint Inhibitors for Lung Cancer Market?
5. What are the technology trends and regulatory frameworks in the Global Immune Checkpoint Inhibitors for Lung Cancer Market?
6. What is the market share of the leading vendors in the Global Immune Checkpoint Inhibitors for Lung Cancer Market?
7. What modes and strategic moves are considered suitable for entering the Global Immune Checkpoint Inhibitors for Lung Cancer Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High prevalence of lung cancer necessitating immune checkpoint inhibitors
5.1.1.2. Government investment in cancer research and treatment
5.1.1.3. Increasing product approval by regulatory agencies
5.1.2. Restraints
5.1.2.1. Limited affordability and reimbursement for immune checkpoint inhibitor therapies
5.1.3. Opportunities
5.1.3.1. Development of promising predictive biomarkers for immune checkpoint inhibitor therapies
5.1.3.2. Combination of immune checkpoint inhibitors with other cancer therapies
5.1.4. Challenges
5.1.4.1. Lack of research standardization of checkpoint inhibitors
5.1.4.2. Possible side-effects of immune checkpoint inhibitors
5.2. Cumulative Impact of COVID-19

6. Immune Checkpoint Inhibitors for Lung Cancer Market, by Types
6.1. Introduction
6.2. CTLA-4 Inhibitors
6.3. PD-1 Inhibitors
6.4. PD-L1 Inhibitors

7. Immune Checkpoint Inhibitors for Lung Cancer Market, by Products
7.1. Introduction
7.2. Atezolizumab
7.3. Durvalumab
7.4. Nivolumab
7.5. Pembrolizumab

8. Immune Checkpoint Inhibitors for Lung Cancer Market, by End-Users
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Hospitals
8.4. Pharmaceutical & Biotechnology Companies

9. Americas Immune Checkpoint Inhibitors for Lung Cancer Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Immune Checkpoint Inhibitors for Lung Cancer Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Immune Checkpoint Inhibitors for Lung Cancer Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. AbbVie Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AstraZeneca plc
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Bayer AG
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. BeyondSpring Pharmaceuticals Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. BioLineRx Ltd.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. BridgeBio Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bristol-Myers Squibb Company
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Celgene Corporation
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. F. Hoffmann-La Roche AG
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Genentech, Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. IQVIA Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Jazz Pharmaceuticals
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Mirati Therapeutics Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Ono Pharmaceutical Co. Ltd
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Philogen S.p.A.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing